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Abstract
Backgroud: Recently, mast cells have been recognized to express several Toll-like receptors
(TLRs) on their membrane surfaces, and granulocyte-macrophage colony-stimulating factor (GM-
CSF) was reported to be able to alter expression of TLRs and cytokine production in neutrophils.
However, whether GM-CSF modulates the expression of TLR and cytokine production in mast
cells is not clear.
Results: Using flow cytometry and real time PCR techniques, we found that GM-CSF upregulated
expression of TLR3 and TLR7 in P815 cells in a concentration dependent manner. GM-CSF also
provoked approximately up to 2.4 and 2.3 fold increase in IL-13 and IL-6 release from P815 cells,
respectively following 16 h incubation. GM-CSF induced IL-13 secretion, TLR3 and TLR7
expression appeared to be through activation of mitogen-activated protein kinase (MAPK) and
phosphotidylinositol 3-kinase (PI3K)/Akt signaling pathways, whereas GM-CSF elicited IL-6 release
seemed via Akt signaling pathway. At 10 ng/ml, GM-CSF significantly enhanced R-848-induced IL-6
release from P815 cells.
Conclusion: The ability of GM-CSF in modulation of expression of TLR3 and TLR7 in P815 mast
cells and in stimulation of IL-13 and IL-6 release from P815 mast cells in vitro suggests that GM-
CSF might play an important role in enhancing the innate immune responses of mast cell to viral
infection
Background
GM-CSF is a cytokine which has been shown to actively
participate in regulation of TLR expression and cytokine
production in inflammatory cells. For example GM-CSF
upregulates expression of TLR2 in human neutrophils and
monocytes [1], elicits IL-8 release from neutrophils
through TLR2 [2], and enhances expression of TLR4 [1]
and TLR9 [3] in neutrophils. Administration of anti-GM-
CSF antibody after LPS challenge effectively reduced neu-
trophil counts and endotoxin-induced TLR4 expression in
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the lungs of BALB/c mice [4], indicating that GM-CSF may
contribute to a protective immunity against bacteria infec-
tion. As an active proinflammatory cytokine, GM-CSF can
be generated by several cell sources including T and B lym-
phocytes, macrophages, keratinocytes, eosinophils, neu-
trophils, and mast cells [5]. The reports that human mast
cells can produce substantial level of GM-CSF following
bacterial PGN activation [6], and human cord blood-
derived mast cells and human mast cell line (HMC-1) can
release GM-CSF in response to IgE [7] or calcium iono-
phore A23187 [8], suggest that GM-CSF is likely to affect
mast cell functions.
Mast cells have long been recognized as the primary effec-
tor cells of allergy [9]. However, recent insight into mast
cells has revealed this cell type as key players in the regu-
lation of innate [10] as well as adaptive immunity
through TLRs [11,12]. It was found that Peptidoglycan
(PGN) from Staphylococcus aureus stimulated bone mar-
row-derived mast cells in a TLR2-dependent manner to
produce TNF-alpha, IL-4, IL-5, IL-6 and IL-13 [13-15],
whereas LPS from Escherichia coli stimulated mast cells in
a TLR4-dependent manner to produce TNF-alpha, IL-
1beta, IL-6, and IL-13 [13,16-18]. Poly(I:C), R-848, and
CpG oligodeoxynucleotide, which are TLR3, TLR7, and
TLR9 activators was able to induce proinflammatory
cytokines (TNF-alpha and IL-6) and chemokines
(RANTES, MIP-1alpha, and MIP-2) release from murine
fetal skin-derived cultured mast cells [19]. However, the
mechanisms through which these TLR expressions on
mast cells and cytokine release from mast cells were regu-
lated remain poorly understood.
TLRs are a group of single membrane-spanning non-cata-
lytic receptors that recognize structurally conserved path-
ogen-associated molecular patterns derived from
microbes, and activate immune cell responses [20,21].
Among the 11 known TLRs, TLR3 has been shown to be
present in human [22] and murine mast cells [23], which
responds to viral double-stranded RNA and single-
stranded RNA of selected species [22]. TLR7 has also been
found in human [23] and murine mast cells [19], which
can be recognized by synthetic imidazoquinoline as well
as several single-stranded RNA sequences of viral origin
[24]. Similarly, TLR9 have been located in human [25] or
murine mast cells [19], which can be activated by DNA
sequences that are rare in mammalian genomes but com-
mon in the genetic materials of bacteria, fungi, and DNA
viruses [25]. Since TLRs are receptors for micro-organism
pathogens, mast cells highly express them, GM-CSF can
regulate TLR expression and cytokine production in
inflammatory cells, we anticipate that GM-CSF ought to
regulate TLR expression and cytokine production in mast
cells, and through which participate in innate immunity
against bacterial and viral invasion. We found that GM-
CSF were able to upregulate expression of TLR3 and TLR7
on P815 mast cells and provoke IL-13 and IL-6 release
from P815 mast cells in the present study.
Results
Expression of TLRs in P815 cells
In order to ensure if P815 cells are the appropriate cells for
the investigation of regulatory effect of GM-CSF on TLR
expression, we first examine the expression of TLRs in
these cells. With RT-PCR analysis, we showed that P815
cells express mRNAs of TLR3, TLR7 and TLR9 (Fig 1A).
Using flow cytometry analysis (Fig 1B) and immunofluo-
Analysis of expression of TLRs on P815 cells Figure 1
Analysis of expression of TLRs on P815 cells. (A) For 
RT-PCR analysis, the gene products were separated in a 1.5% 
agarose gel. Lane 1–5 represented DNA marker, β-actin (288 
bp), TLR3 (240 bp), TLR7 (262 bp) and TLR9 (297 bp), 
respectively. (B) For flow cytometry analysis, cells were incu-
bated with FITC-conjugated goat anti-mouse TLR9 mono-
clonal antibody or incubated with rabbit anti-mouse TLR3, 
TLR7 polyclonal antibodies at 37°C for 1 h. (C) For immun-
ofluorescent microscopy, cells were treated with the above-
mentioned procedures and analyzed with a laser scanning 
confocal microscope.BMC Cell Biology 2009, 10:37 http://www.biomedcentral.com/1471-2121/10/37
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rescent cell staining (Fig 1C) techniques, we confirmed
that P815 cells also express TLR3, TLR7 and TLR9 pro-
teins.
Modification of expression of TLRs in P815 cells by GM-
CSF
In order to examine if GM-CSF induces altered expression
of TLR3, TLR7 and TLR9 mRNA, quantitative real time RT-
PCR was employed. The results showed that GM-CSF at
1.0 to 100 ng/ml up-regulated expression of TLR3 and
TLR7 mRNAs in P815 cells in a concentration dependent
manner. Up to approximately 9.5 fold increase in TLR3
mRNA expression was observed in P815 cells. GM-CSF
induced up-regulation of TLR3 mRNA expression initi-
ated at 2 h, peaked at 6 h, and declined at 16 h following
incubation (Fig. 2A). GM-CSF provoked enhancement of
TLR7 mRNA expression appeared a slow process, and a
dose dependent curve was achieved only at 16 h following
incubation. Up to approximately 4.5 fold increase in
expression of TLR7 mRNA was observed in P815 cells (Fig.
2B). GM-CSF at the concentrations tested had little effect
on TLR9 mRNA expression (data not shown).
We then used flow cytometry analysis technique to deter-
mine if GM-CSF stimulates increased expression of TLR3
and TLR7 proteins. The results showed that GM-CSF at 0.1
to 100 ng/ml provoked upregulation of expression of
TLR3 and TLR7 in P815 cells in a dose dependent manner
following 16 h incubation period. Approximately up to
52% and 96.3% upregulated expression of TLR3 and TLR7
was observed when cells were incubated with 100 ng/ml
of GM-CSF for 16 h (Fig 2C). The heat treatment com-
pletely abolished the ability of GM-CSF in upregulation of
TLR3 and TLR7 protein expression (Fig 2C). The time
course study showed that significant up-regulation of
expression of TLR3 and TLR7 by GM-CSF was first
observed at 6 h, and lasted at least to 16 h following incu-
bation (Fig 2D). In the parallel experiments, immunoflu-
orescent analysis showed similar pattern of increased
expression of TLR3 and TLR7 in P815 cells following 2, 6
and 16 h incubation periods (data not shown). With flow
cytometry analysis and immunofluorescent staining tech-
niques, it was shown that GM-CSF failed to alter TLR9
expression in P815 cells (data not shown).
Induction of cytokine secretion from P815 cells by GM-CSF
GM-CSF has been shown to elicit IL-8 release from neu-
trophils through TLR2. However, little is known of the
ability of GM-CSF in induction of cytokine release from
mast cells. In order to examine if GM-CSF can induce
cytokine release from mast cells, P815 cells were chal-
lenged with GM-CSF, and levels of IL-6, IL-12 and IL-13
were measured. They represent proinflammatory
cytokines (IL-6), Th1 cytokines (IL-12) and Th2 cytokines
(IL-13), respectively. The results showed that GM-CSF at
0.1 to 100 ng/ml induced a concentration dependent
release of IL-6 from P815 cells following 16 h incubation.
Approximately up to 2.3 fold increase in IL-6 release was
achieved when 100 ng/ml of GM-CSF was incubated with
cells (Fig 3A). Similarly, GM-CSF provoked approximately
up to 2.4 fold increase in IL-13 release from P815 cells fol-
lowing 16 h incubation (Fig 3B). Preincubation of anti-
GM-CSF antibody with cells for 30 min significantly elim-
inated GM-CSF induced IL-6 and IL-13 secretion (Fig 3A,
B). GM-CSF also elicited significant release of IL-6 (Fig
3A) and IL-13 (Fig 3B) from P815 cells at 6 h following
incubation. GM-CSF at the concentrations examined had
little effect on IL-12 secretion from P815 cells (data not
shown).
Effect of GM-CSF on poly (I:C) and R-848-induced IL-6 
release from P815 cells
In order to determine if GM-CSF affect poly (I:C) and R-
848 induced IL-6 release. P815 cells were preincubated
Induction of upregulated expression of TLR3 (A), TLR7 (B)  mRNAs and TLR3 (C), TLR7 (D) proteins in P815 cells by  GM-CSF Figure 2
Induction of upregulated expression of TLR3 (A), 
TLR7 (B) mRNAs and TLR3 (C), TLR7 (D) proteins 
in P815 cells by GM-CSF. For real-time PCR analysis, cells 
were treated with various concentrations of GM-CSF at 
37°C for 2, 6 and 16 h, respectively. The data were normal-
ized to the housekeeping gene (β-actin gene) and were 
expressed as Mean ± SE fold over control for four separate 
experiments performed in duplicate. For flow cytometry 
analysis, the cells were incubated with various concentrations 
of GM-CSF for 16 h (C) or with 100 ng/ml of GM-CSF for 2, 
6 and 16 h (D). ht-GM-CSF represented the heat-treated 
GM-CSF (100 ng/ml). Values shown are Mean ± SE for four 
separate experiments performed in duplicate. * P < 0.05 
compared with the response to corresponding medium alone 
control.BMC Cell Biology 2009, 10:37 http://www.biomedcentral.com/1471-2121/10/37
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with GM-CSF for 1 h before adding Poly (I:C) and R-848
for 6 h. The results showed that GM-CSF at 10 ng/ml sig-
nificantly enhanced R-848-induced IL-6 release, and at
100 ng/ml had additive effect on poly (I:C) and R-848-
induced IL-6 release from P815 cells (Fig 4).
Effect of cell signaling inhibitors on GM-CSF-induced 
release of cytokines and upregulated expression of TLR3 
and TLR7
Little information on GM-CSF signal pathways of mast
cells is available, but the findings that GM-CSF modulates
neutrophil response to bacterial DNA by activation of the
mitogen-activated protein kinase (ERK)1/2 [26], and that
IL-12 induced IL-4 release through activation of ERK and
Akt signaling pathways in P815 mast cell line [27] may
give us a clue to explore the possible signaling pathways
in P815 cells. We therefore employed PD98059 a MAPK
pathway inhibitor, U0126 an inhibitor of MEK and thus a
MAPK pathway inhibitor, SB203580 a selective inhibitor
of p38 MAPK, LY294002 a PI3K inhibitor and AG490 a
Janus kinase (JAK)/STAT3 pathway inhibitor to investi-
gate the potential GM-CSF signal pathways in P815 cells.
PD98059, U0126 and LY294002 almost completely abol-
ished GM-CSF-induced IL-13 release from P815 cells
when they were preincubated with the cells for 30 min
(Fig 5A), indicating that GM-CSF induced IL-13 release is
through activation of MAPK and PI3K/Akt signaling path-
ways. In contrast, SB203580, U0124 a structural analogue
negative control of U0126 and AG490 had little influence
on GM-CSF induced IL-13 release (data not shown).
Induction of IL-6 (A) and IL-13 (B) release from P815 cells by  GM-CSF Figure 3
Induction of IL-6 (A) and IL-13 (B) release from P815 
cells by GM-CSF. Cells were incubated with various con-
centrations of GM-CSF (ng/ml) or GM-CSF with its blocking 
antibody (Ab, μg/ml) at 37°C for 6 and 16 h. Values shown 
are Mean ± SE for four separate experiments performed in 
duplicate. * P < 0.05 compared with the response to corre-
sponding medium alone control.
Effect of GM-CSF on poly (I:C) and R-848 induced IL-6 secre- tion from P815 cells Figure 4
Effect of GM-CSF on poly (I:C) and R-848 induced IL-
6 secretion from P815 cells. The cells were preincubated 
with GM-CSF for 1 h before adding poly (I:C) or R-848 for 6 
h. Values shown are Mean ± SE for four separate experi-
ments performed in duplicate. * P < 0.05 compared with the 
response to corresponding medium alone control. † P < 0.05 
compared with the response to R-848 5.0 μg/ml alone. Poly 
= poly (I:C).BMC Cell Biology 2009, 10:37 http://www.biomedcentral.com/1471-2121/10/37
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LY294002 also completely abolish GM-CSF induced IL-6
release (Fig 5B), indicating that GM-CSF induced IL-6
release is through activation of PI3K/Akt signaling path-
way. All inhibitors tested did not significantly affect basal
IL-6 and IL-13 release. PD98059 also completely abol-
ished GM-CSF induced upregulation of TLR3 (Fig 6A) and
TLR7 (Fig 6B) expression, and U0126 eliminated GM-CSF
induced enhancement of TLR7 expression, indicating that
the actions of GM-CSF are via activation of MAPK signal-
ing pathway. Similarly, LY294002 completely abolish
GM-CSF induced upregulation of TLR3 and TLR7 expres-
sion (Fig 6), indicating GM-CSF induced upregulation of
TLR3 and TLR7 expression is through activation of PI3K/
Akt signaling pathway. As expected, SB203580, U0124
Effect of PD98059 (PD), U0126, U0124 and LY294002 (LY)  on GM-CSF induced IL-13 (A) and IL-6 (B) secretion from  P815 cells Figure 5
Effect of PD98059 (PD), U0126, U0124 and LY294002 
(LY) on GM-CSF induced IL-13 (A) and IL-6 (B) 
secretion from P815 cells. Cells were preincubated with 
PD (50 μM), U0126 (5 μM), U0124 (5 μM) or LY (20 μM), 
respectively for 30 min before GM-CSF (10 and 100 ng/ml) 
being added for 6 h at 37°C. Values shown are Mean ± SE for 
four separate experiments performed in duplicate. * P < 0.05 
compared with the response to corresponding uninhibited 
control.
Effect of PD98059 (PD), U0126, U0124 and LY294002 (LY)  on GM-CSF upregulated TLR3 (A) and TLR7 (B) expression  in P815 cells Figure 6
Effect of PD98059 (PD), U0126, U0124 and LY294002 
(LY) on GM-CSF upregulated TLR3 (A) and TLR7 
(B) expression in P815 cells. Cells were preincubated 
with PD (50 μM), U0126 (5 μM), U0124 (5 μM) or LY (20 
μM), respectively for 30 min before GM-CSF (10 and 100 ng/
ml) being added for 6 h at 37°C. Values shown are Mean ± SE 
for four separate experiments performed in duplicate. * P < 
0.05 compared with the response to corresponding uninhib-
ited control.BMC Cell Biology 2009, 10:37 http://www.biomedcentral.com/1471-2121/10/37
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and AG490 had little influence on GM-CSF induced
upregulation of TLR3 and TLR7 expression (data not
shown). All inhibitors tested did not significantly affect
basal TLR3 and TLR7 expression in P815 cells.
Inhibition of GM-CSF-induced phosphorylation of ERK 
and Akt by signaling inhibitors
PD98059 and U0126 inhibited approximately up to 50
and 46.7% of GM-CSF induced phosphorylation of ERK,
and LY294002 diminished GM-CSF-induced phosphor-
ylation of Akt by approximately 76.2%, respectively in
P815 cells following 30 min preincubation period.
Discussion
It was found for the first time that GM-CSF was able to
upregulate expression TLR3 and TLR7 and to stimulate IL-
13 and IL-6 from mast cells. Since MAPK pathway inhibi-
tors and PI3K inhibitor inhibited GM-CSF induced
expression of TLR3 and TLR7 as well as IL-13 and IL-6
secretion, it is most likely that GM-CSF induced IL-13 and
IL-6 secretion is through TLR3 and TLR7 related mecha-
nisms. GM-CSF could also prime the cells to respond to R-
848 a TLR7 ligand stimulation. The previous findings that
TLR3 [22], TLR7 [22] and TLR9 [25] are present in mast
cells, and that GM-CSF can regulate expression of TLR2
and TLR4 in neutrophils [1-3] support our observation
above.
As the main TLR related to the viral recognition, TLR3
have been shown to be able to respond to viral RNAs of
selected species, and resulted in production of IFN-β and
RANTES/CCL5 that are critical in regulating T-cell func-
tions [28]. Moreover, TLR3-activated mast cells elicited
strong chemotactic responses to CD8+ T cells in vitro and
in vivo [29]. Like TLR3, TLR7 has also been demonstrated
to recognize several single-stranded RNA sequences of
viral origin. TLR7 activators, R-848 could activate murine
mast cell to release proinflammatory cytokine (TNF-α and
IL-6) and chemokines (RANTES, MIP-1α and MIP-2), and
these factors, in turn, can contribute to antiviral effects
[19]. Recent study found that mucosal activation of TLR7
by virus is one of the main mechanisms for the mast cell-
dependent anorexia and hypothermia [24]. Since TLR3
and TLR7 play critical roles in innate immune recognition
of virus, our results suggest that GM-CSF is likely to play a
promising role as immunodulator for enhancing virus rec-
ognition by mast cells.
To confirm the potential pivotal role of GM-CSF in immu-
nity, we measured the levels of IL-12, IL-13 and IL-6 in
GM-CSF treated cell supernatant. Instead of induction of
IL-12 production, GM-SCF elicited a significant IL-13
release from P815 cells. Since IL-13 is emerging as an
important mediator in the development of Th2 cell
responses, which can induce IgE secretion from activated
human B cells [30] and acts more prominently as a molec-
ular bridge linking allergic inflammatory cells to the non-
immune cells [31], we believe that GM-SCF also play a
role in acquired immune response such as allergic reac-
tions. GM-SCF has been implicated in allergic inflamma-
tion in the previous studies. It was reported that a higher
proportion of cells expresses GM-CSF mRNA in broncho-
alveolar lavage (BAL) fluid from asthma patients com-
pared with healthy controls [32]. When asthma patients
were challenged with allergen, GM-CSF levels increased in
the BAL fluid, and the levels correlated with the number
and percentage of BAL eosinophils [33]. Administration
of a GM-CSF-neutralizing mAb attenuated allergic airway
inflammation in a murine model of asthma, significantly
reducing airway hyperresponsiveness, airway eosi-
nophilia, and pulmonary inflammation [34]. IL-6 has
long been recognized as a potent proinflammatory
cytokine, which can be released from activated mast cells
[35] and contributes to local inflammation and vessel
expansion in airway walls of asthmatics [36]. Induction of
IL-6 from P815 cells by GM-SCF proves further that GM-
CSF participates in the pathogenesis of inflammation.
GM-CSF induced IL-13 secretion appeared to be through
activation of MAPK and PI3K/Akt signaling pathways,
whereas GM-CSF elicited IL-6 release seemed via PI3K/Akt
signaling pathway as MAPK pathway inhibitors or PI3K
inhibitor inhibited GM-CSF induced IL-13 or IL-6 secre-
tion. While little information on GM-CSF signal pathways
of mast cells is available, a study which showed that GM-
CSF modulates the CpG-independent, MyD88-dependent
neutrophil response to bacterial DNA, by increasing the
activation of the ERK1/2 [26] may help to understand our
above observations. The work demonstrated that C3a
stimulated substantial MCP-1 and RANTES/CCL5 produc-
tion, and ERK and Akt phosphorylation in human LAD 2
mast cells [37]; and our former study that IL-12 induced
IL-4 release through activation of ERK and Akt signaling
pathways in P815 mast cell line [27] may support our cur-
rent findings.
Conclusion
The ability of GM-CSF in modulation of expression of
TLR3 and TLR7 in P815 mast cells and in stimulation of
IL-13 and IL-6 release from P815 mast cells in vitro sug-
gests that GM-CSF might play an important role in
enhancing the innate immune responses of mast cell to
viral infection
Methods
Reagents and cells
Paraformaldehyde, bovine serum albumin (BSA, fraction
V) and 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-
(4-pyridyl)-1H-imidazole (SB203580) were from Sigma
Inc. (St Louis, MO, USA). Recombinant mouse GM-CSF,BMC Cell Biology 2009, 10:37 http://www.biomedcentral.com/1471-2121/10/37
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anti-mouse GM-CSF monoclonal antibody (mAb) was
from R&D Systems (Minneapolis, MN, USA). Tissue cul-
ture reagents including Dulbecco's modified Eagle's
medium (DMEM), HEPES and fetal bovine serum (FBS)
were obtained from GibcoBRL (Carlsbad, CA, USA). Cel-
lular activation of signaling ELISA CASE kits for Akt, ERK,
p38 MAPK and signal transducer and activators of tran-
scription (STAT)3 were from SuperArray Bioscience Cor-
poration (Frederick, MD, USA). Mouse IL-6, IL-12 and IL-
13 ELISA kits were from Pierce Biotechnology Inc. (Rock-
ford, IL, USA). 2-(2-Diamino)-3-methoxyphenyl-4H-1-
benzopyran-4-one (PD98059), 1,4-diamino-2,3-dicyano-
1,4-bis(2-aminophynyltio)butadiene (U0126), tyrphos-
tin (AG490), 1,4-diamino-2,3-dicyano-1,4-bis(methyl-
thio) butadiene (U0124) and 2-(4-morpholinyl)-8-
phenyl-4H-1-benzopyran-4-one (LY294002) were from
Cell Signaling Technology (Beverly, MA, USA). TRIzol
Reagent and SYBR Green I Stain were from Invitrogen
(Carlsbad, CA, USA). ExScript RT reagent kit and SYBR
Premix Ex Taq (perfect real time) was from TaKaRa Bio-
technology Co. Ltd (DaLian, China). FITC-conjugated rat
anti-mouse TLR9 mAb, FITC-conjugated rat isotype con-
trol, rabbit anti-mouse TLR3 and TLR7 mAbs were from
eBioScience (Los Angeles, CA, USA). FITC-conjugated
goat anti-rabbit polyclonal antibody was from BD
Pharmingen (San Jose, CA, USA). Poly (I:C) and R-848
were from Invivogen (San Diego, CA, USA). The mouse
mastocytoma cell line (P815) was obtained from the
American Type Culture Collection (ATCC, Manassas, VA,
USA). Most of other reagents such as salt and buffer com-
ponents were analytical grade and obtained from Sigma.
P815 cell culture and challenge
P815 cells were cultured with ATCC complete growth
medium including DMEM with 4 mM L-glutamine, 1.5
mg/ml sodium bicarbonate, 4.5 mg/ml glucose, 10% FBS,
100 U/ml penicillin and 100 mg/ml streptomycin in 75-
cm2 tissue culture flasks (Falcon) at 37°C in a 5% (v/v)
CO2, water-saturated atmosphere. P815 cells at a density
of 1 × 106 cells/ml were incubated with the serum-free
basal medium for 6 h and washed twice before challenge.
For challenge experiments, cells were exposed to various
concentrations of GM-CSF (0.1–100 ng/ml) with or with-
out its blocking antibody (10, 30 μg/ml). Heat-treated
GM-SCF (ht-GM-CSF) was prepared by incubation of GM-
SCF at 100°C for 10 min, and was used as irrelevant pro-
tein control for challenge experiment. At 2, 6 or 16 h fol-
lowing incubation, the culture plates were centrifuged at
450 g for 10 min at 25°C. After the supernatant (5 ml)
being collected and stored at -80°C, the cell pellet con-
taining approximately 5 × 106 cells were resuspended for
immunofluorescence and real-time PCR analysis.
For certain experiments, cells were preincubated with 10
ng/ml and 100 ng/ml of GM-CSF for 1 h before adding 2.5
and 25 μg/ml of poly (I:C) or 0.5 and 5.0 μg/ml R-848. At
6 h following incubation, the culture plates were centri-
fuged at 450 g for 10 min at 25°C. The culture superna-
tants were collected and stored at -80°C for further use.
For cell signalling experiments, cultured cells at a density
of 1.5 × 106 cells/ml were washed twice with the serum-
free basal medium and then treated with the inhibitors of
cell signalling pathways including PD98059 (50 μM),
U0126 (5 μM), U0124 (5 μM), SB203580 (20 μM),
LY294002 (20 μM) and AG490 (40 μM) for 30 min before
being challenged with GM-CSF (10 and 100 ng/ml) for 15
min, 2 or 6 h. Following incubation, 400 μl of cell suspen-
sion from each well was removed for signaling ELISA anal-
ysis, and the remaining 700 μl of cell suspension was
centrifuged at 450 g for 10 min at 25°C. The culture super-
natants were then collected and stored at -80°C, and cells
(~1 × 106) were resuspended for immunofluorescence
analysis.
Examination of expression of TLR mRNAs
The expression of TLR mRNAs in P815 cells was deter-
mined with RT-PCR. Total RNA was isolated by using a
TRIzol reagent kit according to the manufacturer's instruc-
tion. Briefly, cells were collected by centrifugation and
lysed directly by adding TRIzol reagent (1 ml per 1 × 106
cells). After being treated with chloroform, RNA was pre-
cipitated by adding 0.5 ml of isopropyl alcohol and then
resuspended with 1 ml of 75% (v/v) ethanol. Total RNA
was quantified by measuring absorbance ratios at 260/
280 nm. The cDNA was prepared by reverse transcriptase
using a commercial RNA-PCR kit according to the manu-
facturer's instruction. For each reaction, 1 μg of total RNA
was reversely transcribed using oligo-d (T). The cDNA was
amplified using forward and reverse specific primers for
amplifying mouse TLRs. β-actin was used as an internal
control. Primers were designed according to the genbank
sequences for mouse TLRs and summarized in Table 1.
The conditions for amplification were as follows: 95°C
for 5 min, 30 cycles of denaturation at 95°C for 30 s,
annealing temperatures as shown in Table 1 for 30 s, and
extension at 72°C for 30 s. PCR products were electro-
phoresed on 1.5% agarose gels that were stained with
SYBR Green I Nucleic Acid Gel Stain and photographed
under ultraviolet (UV) light.
Quantitative real-time PCR
Quantitative expression of TLR mRNAs in P815 cells was
determined by real-time PCR following the manufacture's
protocol. Briefly, after synthesizing cDNA from 1 μg of
total RNA by using ExScriptTM RT reagent kit, real-time
PCR was performed by using SYBR® Premix Ex Taq TM on
the ABI Prism 7000 Sequence Detection System (Perkin
Elmer Applied Systems, Foster City, CA, USA). Each reac-
tion contains 12.5 μl of 2 × SYBR green Master Mix, 1 μlBMC Cell Biology 2009, 10:37 http://www.biomedcentral.com/1471-2121/10/37
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of 10 μM of primers, 1 μl of the cDNA, to a total volume
of 25 μl. The thermal cycling conditions included an ini-
tial denaturation step at 50°C for 2 min, 95°C for 10 min;
40 cycles at 95°C for 15 s, annealing temperatures as
shown in Table 1 for 30 s and extension at 72°C for 30 s.
Consequently, at the end of the PCR cycles, specificities of
the amplification products were controlled by dissocia-
tion curve analysis. mRNA expression in each sample was
finally determined after correction with β-actin expres-
sion. The gene specific threshold cycle (Ct) for each sam-
ple (ΔCt) was corrected by subtracting the Ct for the
housekeeping gene β-actin. Untreated controls were cho-
sen as the reference samples, and the ΔCt for all experi-
mental samples were subtracted by the ΔCt for the control
samples (ΔΔCt). The magnitude change of test gene
mRNA was expressed as 2-ΔΔCt. Each measurement of a
sample was conducted in duplicate.
Flow cytometry analysis
P815 cells were pelleted by centrifugation at 450 g for 10
min, and then fixed in 2% paraformaldehyde for 30 min.
After washing, the cells were resuspended in phosphate-
buffered saline (PBS). For TLR9 staining, cells were incu-
bated with FITC-conjugated rat anti-mouse TLR9 mAb or
FITC-conjugated rat isotype control (all at a final concen-
tration 4 μg/ml) at 37°C for 1 h. For TLR3 and TLR7 stain-
ing, cells were incubated with rabbit anti-mouse TLR3 and
TLR7 polyclonal antibodies or normal rabbit IgG, respec-
tively (all at a final concentration 2 μg/ml) at 37°C for 1
h. After two washes with 1% BSA/PBS, cells were incu-
bated with 1 μg/ml of FITC-conjugated goat anti-rabbit
polyclonal antibody at 37°C for 1 h. Cells were finally
resuspended in PBS and analyzed on a FACSCalibur flow
cytometer with CellQuest software (BD Biosciences).
Immunofluorescent cell staining
After being fixed in 2% paraformaldehyde for 30 min,
P815 cells were incubated with 3% normal serum block-
ing solution for 10 min. The same staining procedures
were used as for the flow cytometry analysis. For TLR9
staining, cells were incubated with FITC-conjugated rat
monoclonal antibody against mouse TLR9, or FITC-con-
jugated rat isotype control (all at a final concentration 4
μg/ml) at 37°C for 1 h. For TLR-3 and TLR7 staining, cells
were incubated with rabbit anti-mouse TLR-3 and TLR7
polyclonal antibodies or normal rabbit IgG, respectively
(all at a final concentration 2 μg/ml) at 37°C for 1 h. After
two washes with 1%BSA/PBS, cells were incubated with 1
μg/ml of FITC-conjugated goat anti-rabbit polyclonal
antibody at 37°C for 1 h. Images were obtained on a Zeiss
5 LIVE confocal laser scanning microscope (Zeiss, Ger-
man).
Determination of optimal concentration of inhibitors for 
signal transduction
To determine the optimal concentrations of the inhibitors
of signal-transduction pathways in P815 cells, 10, 20, 25,
50 and 100 μM of PD98059, 2, 2.5, 5 and 10 μM of
U0126, 10, 20, 40 and 80 μM of SB203580, 5, 10, 20 and
40 μM of LY294002 and 10, 20, 40, 80 and 160 μM of
AG490 were preincubated with P815 cells for 30 min
before adding stimulus. Since 50 μM of PD98059, 5 μM
of U0126, 20 μM of SB203580, 20 μM of LY294002 and
40 μM of AG490 almost completely abolished, GM-CSF-
induced phosphorylation of ERK1/2, p38 MAPK, Akt and
STAT3, respectively (data not shown), and induced mini-
mum cell death, they were chosen as the optimal concen-
tration throughout the study.
Determination of levels of cytokines
IL-6, IL-12 and IL-13 levels were measured by using ELISA
kits, according to the manufacturer's instruction.
Analysis of signal-transduction pathways
The phosphorylation of Akt, ERK, p38 and STAT3 was
analyzed by using Cellular Activation of Signaling ELISA
(CASE) kits as described previously [27].
Statistics
Data are expressed as mean ± SEM for the indicated
number of independently performed duplicated experi-
ments. Statistical significance between means was ana-
lyzed by one-way analysis of variance or the Student's t
test utilizing the SPSS 13.0 version. P < 0.05 was taken as
statistically significant.
Abbreviations
(TLRs): Toll-like receptors; (GM-CSF): granulocyte-mac-
rophage colonystimulating factor; (MAPK): mitogenacti-
vated protein kinase; (ERK): extracellular signal-regulated
Table 1: Primers for RT-PCR and real-time RT-PCR
Target
gene
Forward sequence (5'-3') Reverse sequence (5'-3') AS (bp) AT (°C) GA
TLR3 GGTGGTCCCGTTAATTTCCT CCCGAAAACATCCTTCTCAA 240 56 NM_126166
TLR7 TGGAAATTTTGGACCTCAGC TTGCAAAGAAAGCGATTGTG 262 52 NM_133211
TLR9 TGCAGGAGCTGAACATGAAC TAGAAGCAGGGGTGCTCAGT 297 58 NM_031178
β-actin GCTACAGCTTCACCACCACAG GGTCTTTACGGATGTCAACGTC 288 60 NM_007393
AS = amplicon size; AT = annealing temperature; GA = genbank accessionBMC Cell Biology 2009, 10:37 http://www.biomedcentral.com/1471-2121/10/37
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kinase; (STAT): signal transducer and activators of tran-
scription; (RT-PCR): reverse transcription-polymerase
chain reaction.
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